Trial
NCT02371577
Evaluation of the Immune Restoration Potential Of Lenalidomide
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Diego
Collaborators
Celgene Corporation
Condition
Chronic Lymphocytic Leukemia (CLL)
Intervention
Lenalidomide
Why stopped
withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-28